FREMONT, Calif., May 11 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody
therapeutics, announced today the appointment of Marc Better, Ph.D., as Vice
President of Process Sciences.
"We are pleased to have Marc join our company. He brings extensive
technical development experience in the biotechnology and life sciences
sectors," said Bill Ringo, president and chief executive officer of Abgenix.
"His experience with pharmaceutical and biotech companies will provide Abgenix
with the technical proficiency essential for Abgenix to become a fully
integrated biopharmaceutical company."
Before joining Abgenix, Dr. Better was vice president, technical
development at XOMA (US) LLC. He was responsible for process development and
clinical manufacturing operations in the XOMA pilot facility. During his
sixteen-year tenure at XOMA, Dr. Better made significant contributions to
XOMA's technology platforms for product development, including gene cloning
and expression in bacterial, fungal and mammalian cell systems, as well as
protein and peptide recovery and purification.
From 1984 to 1989, Dr. Better held various research positions at
International Genetic Engineering, Inc. (INGENE), which later merged with
XOMA.
Dr. Better is the inventor of more than 20 patents issued in the U.S. and
Europe.
He earned a Ph.D. in biochemistry from Brandeis University, and holds a
B.S. in microbiology from Michigan State University. In addition, he worked
as a postdoctoral fellow at the University of California at San Diego.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid generation,
selection and production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its leadership
position in human antibody technology to build a diversified product portfolio
through its own development efforts and the establishment of collaborations
with multiple pharmaceutical and biotechnology companies. For more information
on Abgenix, visit the company's website at http://www.abgenix.com.
This press release contains forward-looking statements about Abgenix's
product development activities, clinical trials and clinical trial results,
the potential submission of a biologic license application for panitumumab,
collaborative arrangements and process sciences and manufacturing activities.
Such statements are subject to a number of uncertainties that could cause
actual results to differ materially from the statements made, including risks
associated with conducting clinical trials, the progress of research and
product development programs, product manufacturing, regulatory approval
processes and meeting requirements for regulatory approval, competitive
products and services, capital requirements and the extent and breadth of
Abgenix's patent portfolio, and other factors set forth in Abgenix's public
filings with the Securities and Exchange Commission, including the risks
described in Abgenix's quarterly report on Form 10-Q for the quarter ended
March 31, 2005 and annual report on Form 10-K for the year ended December 31,
2004. Abgenix is providing this information as of the date of this press
release and does not undertake any obligation to update any forward-looking
statements.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Aisha Santiago, Corporate Communications &
Investor Relations, of Abgenix, Inc., +1-510-284-6858, or
+1-510-284-6605; or E. Blair Schoeb, Corporate Communications,
+1-212-923-6737, for Abgenix, Inc.
|
